Green bio specialist company Genolution announced on the 15th that it has signed an OEM (contract manufacturing) contract with molecular diagnostic specialist company SML Genitri for a line of nucleic acid extraction reagents.
Through this agreement, Genolution plans to establish a stable mass production system for GeniTree's products, building upon this foundation to expand its domestic clinical network and advance into the global market. In particular, supply expansion is expected to target major diagnostic institutions, such as the Samkwang Medical Foundation.
Through this agreement, the two companies will focus on ensuring consistency and quality in sample preprocessing and nucleic acid extraction processes during molecular diagnostics. Genolution, leveraging its proprietary production infrastructure and process validation capabilities, will be responsible for mass production optimization, process integration management, and quality assurance, while Zenithree will be responsible for product design and core ingredient formulation development.
A Genolution official stated, “This collaboration will be an opportunity to enhance product competitiveness in domestic and international markets by combining Zenithree’s technological prowess with our own manufacturing capabilities,” adding, “We will seek various business opportunities through expanded partnerships that go beyond simple OEM.”
A Zenithree official said, “Consistent quality and rapid supply are important factors for extraction reagents, and through our collaboration with Genolution, we have established a stable production base in domestic and international markets.”
- See more related articles
You must be logged in to post a comment.